my.clevelandclinic.org
Dec 13, 2024, 18:48
Jame Abraham: Pyrotinib and Herceptin with docetaxel in breast cancer
Jame Abraham, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on X:
“Improvement in PFS and OS with combination of Pyrotinib and Herceptin with docetaxel.”
More posts featuring Jame Abraham.
Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.
Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 17, 2025, 18:27
Aug 17, 2025, 18:14
Aug 17, 2025, 17:58
Aug 17, 2025, 16:48